Finapid (minoxidil/finasteride)
Topical Solution, Non-Oral
Last reviewed · Source: First Databank (FDB) drug data
Overview
Minoxidil is a piperidinopyrimidine-derivative vasodilator that possesses hair growth stimulant properties.
Finasteride is a competitive and specific inhibitor of Type II 5alpha-reductase, an intracellular enzyme that convertstestosteroneto 5alpha-dihydrotestosterone (DHT).
Finasteride is a synthetic 4-azasteroid compound. The drug is a specific, competitive inhibitor of steroid type II 5alpha-reductase, an intracellular enzyme present in high concentrations in the liver, skin, and prostate gland. The conversion of testosterone to the active metabolite 5alpha-dihydrotestosterone (DHT) depends on the presence of this enzyme.
5alpha-Reductase is present as 2 distinct isoenzymes, type I and type II, in humans and certain animals. Type I 5alpha-reductase is found principally in the sebaceous and sweat glands of the skin, including scalp, follicular and epidermal keratinocytes, and dermal papilla cells, and also in the liver; this isoenzyme is responsible for approximately one-third of circulating DHT. The Type II isoenzyme is found predominantly in the prostate, seminal vesicles, epididymides, and liver, and is detectable in the inner root sheath of hair follicles and epidermal keratinocytes; this isoenzyme is responsible for two-thirds of circulating DHT.
Although testosterone is the principal circulating androgen, conversion to DHT amplifies the androgenic effect in androgen-sensitive target tissues such as the skin and scalp.
In men with androgenetic hair loss, increased amounts of DHT and 5alpha-reductase lead to miniaturized hair follicles and a shortened hair growth cycle; these alterations are not seen in hairy scalp portions of men with androgenetic hair loss or in patients without alopecia. Evidence that testosterone (and DHT) and steroid 5alpha-reductase may be involved in androgenetic hair loss comes from clinical observations in men with congenital 5alpha-reductase deficiency and in hypogonadal men. Androgenetic hair loss is not observed in these men, and hair loss in hypogonadal men can be induced by administration of testosterone.
In men with congenital 5alpha-reductase deficiency (pseudohermaphroditism), the gene for type II 5alpha-reductase activity is defective, while the gene for type I isoenzyme activity remains unaffected. These data suggest that while the Type II isoenzyme is not as prevalent in human scalp as the Type I isoenzyme, the Type II isoenzyme is involved in the development of androgenetic alopecia.
The exact mechanism of action of finasteride in patients with androgenetic alopecia has not been fully elucidated since the role of 5alpha-reductase and DHT in male-pattern baldness has not been fully elucidated. In vitro binding studies indicate that finasteride inhibits Type II 5alpha-reductase by binding tightly to the enzyme and is 100-fold more selective for this isoenzyme than for the Type I isoenzyme. Inhibition of 5alpha-reductase by finasteride is accompanied by reduction of finasteride to dihydrofinasteride and adduct formation with nicotinamide adenine dinucleotide phosphate (NADP+).
This enzyme complex has a slow rate of turnover in the body (half-life of about 30 days for the Type II isoenzyme complex and 14 days for the Type I complex). Although in vitro studies suggest that finasteride acts principally through Type II 5alpha-reductase, some clinicians suggest that chronic treatment with finasteride also may have some effect on the Type I isoenzyme.
Inhibition of Type II 5alpha-reductase by finasteride blocks the peripheral conversion of testosterone to DHT, resulting in substantial reductions in serum and tissue DHT concentrations. In men with androgenetic alopecia, high-dose oral finasteride (5 mg) decreases scalp DHT concentrations to levels found in hairy scalp, reduces serum DHT, increases hair regrowth, and slows hair loss. Finasteride may affect scalp hair growth through reductions in local and systemic DHT because the scalp is highly vascularized; the relative contributions of reductions in serum and scalp concentrations to the observed increase in scalp hair has not been elucidated.
Finasteride has no affinity for the androgen receptor and has no androgenic, antiandrogenic, estrogenic, antiestrogenic, or progestational effects.
The mean bioavailability of finasteride 1-mg tablets is 65%. At steady-state dosing, peak plasma concentrations were reached in 1 to 2 hours post-dose. The bioavailability of finasteride is not affected by food.
Approximately 90% of circulating finasteride is bound to plasma proteins. The drug crosses the blood-brain barrier. Finasteride is extensively metabolized in the liver, primarily via cytochrome P-450(CYP) enzymes.
The 2 metabolites that have been identified (t-butyl side chain monohydroxylated andmonocarboxylic acid) exhibit no more than 20%of the 5alpha-reductase inhibitory activity of the parent drug. The mean terminal half-life of finasteride is approximately 5-6 hours in men 18-60 years of age and 8 hours in men >70 years of age. Following administration of an oral dose, approximately 39% of the dose is excreted in urine in the form of metabolites and 57% is excreted in feces.
Generic name: minoxidil/finasteride
Therapeutic class: Dermatological
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Finapid
Indications
No indications are available for this drug.
Dosing
When the dropper applicator is used as directed, the applicator delivers 1 mL of minoxidil topical solution (20 or 50 mg of minoxidil in the 2 or 5% solution, respectively). When the metered-spray or extender-spray applicator is used, delivery of a 1-mL dose requires pumping the spray attachment 6 times (i.e., with approximately 3.3 or 8.3 mg of drug per metered spray with the 2 or 5% solution, respectively). When used as directed, each bottle of minoxidil topical solution should last 25-30 days provided substantial amounts of solution are not lost during applicator changes.
Minoxidil solution is applied topically to the scalp. Twice-daily application appears to be necessary for optimum results. Individuals receiving topical minoxidil therapy should be carefully instructed regarding proper use of the solution. To obtain optimum results, these individuals should be given a copy of the instructions provided by the manufacturers.
Topical minoxidil solution is applied to the total affected areas of the scalp using one of the applicators provided by the manufacturers (i.e., metered-spray applicator, extender spray applicator, dropper applicator). The manufacturers' patient information should be consulted for specific methods of application. Individuals being treated for androgenetic alopecia should be advised that because of the risk of adverse systemic effects, the topical preparation is intended for application to the scalp only and should not be applied to other areas of the body.
Prior to application of minoxidil topical solution, the hair and scalp should be dry. Individuals applying minoxidil topical solution with their fingertips should be instructed to wash their hands thoroughly afterward. When the metered-spray or extender-spray applicator is used, inhalation of the spray mist should be avoided.
Finasteride is administered orallywithout regard to meals.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Finasteride does not affect the cytochrome P-450 (CYP) enzyme system. No clinically meaningful drug interactions have been identified. Drugs that have been tested for drug interaction potential with finasteride include antipyrene, digoxin, propranolol, theophylline, and warfarin.
Although specific drug interaction studies have not been performed, finasteride (administered at a dose of 1 mg or higher) was used concomitantly with acetaminophen, acetylsalicylic acid, alpha-blockers, analgesics, angiostensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2receptorantagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory agents, and quinolone anti-infectives in clinical studies without evidence of clinically significant adverse interactions.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
*Pregnancy.
*Hypersensitivity to any component of the medication.
- Dermatosis of the scalp
- Lactation
- Pregnancy
- Suicidal ideation
- Disease of liver
- High-grade prostate cancer
- Malignant tumor of male breast
Adverse reactions
The most common adverse effects reported in >=1% of patients receiving finasteride inclinical studies and more frequentlythan in patients treated with placebo include decreased libido, erectile dysfunction, and ejaculation disorder.
Less Frequent
- Dermatitis due to topical drug
- Pruritus of skin
- Skin rash
- Urticaria
Rare or Very Rare
- Abnormal sexual function
- Alopecia
- Angioedema
- Body fluid retention
- Cardiac arrhythmia
- Chest pain
- Dizziness
- Eczema
- Edema
- Folliculitis
- Head sensation disturbance
- Headache disorder
- Hypotension
- Neuralgia
- Reduced visual acuity
- Tachycardia
- Visual changes
Less Frequent
- Dry skin
- Erythema
Rare or Very Rare
- Vasodilation of blood vessels
Precautions
No enhanced messaging available.
Finasteride is not indicated for use in pediatric patients; safety and efficacy have not been established.
Although there are no adequate and controlled studies to date in humans receiving oral or topical minoxidil, orally administered minoxidil has been associated with evidence of increased fetal resorption in rabbits, but not rats, when given at dosages 5 times the maximum recommended human oral antihypertensive dosage. There was no evidence of teratogenic effects of orally administered minoxidil in rats or rabbits. There was no evidence of teratogenic effects in rats receiving subcutaneous minoxidil dosages of 80 mg/kg daily (about 2000 times the maximal systemic human exposure achieved with daily administration of topical minoxidil); however, maternal toxicity was observed with this dosage. Evidence of developmental toxicity was observed in rats receiving subcutaneous dosages exceeding 80 mg/kg daily. For additional information on the potential risks of oral minoxidil therapy during pregnancy, see Cautions: Pregnancy, Fertility, and Lactation, in Minoxidil 24:08.20. The effects of the drug on labor and delivery are not known.
Finasteride is contraindicated in women who are or maybecome pregnant.
Because of the ability of Type II 5alpha-reductase inhibitors toinhibit the conversion of testosterone to 5alpha-dihydrotestosterone (DHT), finasteridemay cause abnormalities of the external genitalia of a male fetus. If finasteride is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the male fetus.
In animal studies, finasteride caused abnormal development of external genitalia in male fetuses. A dose-dependent increase in hypospadias was observed in 3.6 to 100% of male offspring in an embryo-fetal development study where pregnant rats received oral finasteride at maternal doses of approximately 1 to 684 times the recommended human dose (RHD) of 1mg/day during theperiod of major organogenesis (gestation days 6 to 17); days 16 to 17 ofgestation is a critical period in male fetal rats for differentiation of the external genitalia. At oral maternal doses approximately 0.2 times the RHD (based on AUC at animal doseof 0.03 mg/kg/day), male offspring had decreased prostatic and seminal vesicularweights, delayed preputial separation, and transient nipple development. Decreasedanogenital distance occurred in male offspring of pregnant rats that receivedapproximately 0.02 times the RHD. No abnormalities were observed in female offspring exposed to any dose of finasteridein utero. In addition, no developmental abnormalities were observed in the offspring of untreated femalesmated with finasteride-treated male rats that received approximately 488 times the RHD. In another study in rhesus monkeys, administration of an oral dose of finasteride (2 mg/kg/day or approximately120,000 times the highest estimated blood levels of finasteride from semen of mentaking 1 mg/day) to pregnant monkeys resulted in external genital abnormalities in malefetuses.
Minoxidil is distributed into milk after oral administration. Because of the potential for serious adverse effects in nursing infants if topically applied drug were absorbed percutaneously and distributed into breast milk, the manufacturer recommends that minoxidil topical solution not be administered to nursing women.
Finasteride is not indicated for use in women. It is not known whether the drug is distributed into human milk.
No dosage adjustment is necessary in geriatic patients.
Clinical studies of finasteridefor androgenetic alopeciadid not include patients 65 years of age and older. Basedon the pharmacokinetics of finasteride 5 mg, the manufacturer states that no dosage adjustment is necessary in theelderly; however, efficacy of the drug has not been established in this population.
The elimination rate of finasteride decreases slightly with increasing age of the patient, with a half-liferanging from approximately 5-6 hours in men 18-60 years of age to 8 hours in men older than 70 years of age.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.